SCHEMBL6687302

SCHEMBL6687302

O=POc1nc2ccccc2[nH]c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAUR Q03405 1/20 0.53
KDM4E B2RXH2 11/20 0.50
NPC1 O15118 8/20 0.50
RAB9A P51151 8/20 0.50
PDGFRB P09619 1/20 0.49
FGFR1 P11362 1/20 0.49
KDR P35968 1/20 0.49
ALDH1A1 P00352 6/20 0.49
KHK P50053 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 4/20 0.46
HSD17B10 Q99714 4/20 0.46
HTT P42858 3/20 0.46
GAA P10253 2/20 0.46
PYGM P11217 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
GBA1 P04062 1/20 0.45
MAPT P10636 1/20 0.45
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5774049 0.79 PLAUR (0.56) PLAURKDM4ENPC1RAB9APDGFRB
SCHEMBL6687300 0.78 PLAUR (0.50) PLAURKDM4ENPC1RAB9APDGFRB
SCHEMBL11365151 0.77 PLAUR (0.53) PLAURKDM4ENPC1RAB9APDGFRB
SCHEMBL8755403 0.75 HPGD (0.55) PLAURKDM4ENPC1RAB9AALDH1A1
SCHEMBL1902269 0.70 RAB9A (0.69) PLAURKDM4ENPC1RAB9APDGFRB
SCHEMBL1029154 0.69 PLAUR (0.61) PLAURKDM4ENPC1RAB9APDGFRB
SCHEMBL30682553 0.69 PLAUR (1.00) PLAURKDM4ENPC1RAB9APDGFRB
SCHEMBL1589916 0.69 PLAUR (0.61) PLAURKDM4ENPC1RAB9APDGFRB
SCHEMBL30617972 0.69 PLAUR (0.61) PLAURKDM4ENPC1RAB9APDGFRB
SCHEMBL16403339 0.69 PLAUR (0.61) PLAURKDM4ENPC1RAB9APDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004078714-A2 PROCESSES FOR PREPARING IMIDAZOQUINOXALINONES, HETEROCYCLIC-SUBSTITUTED IMIDAZOPYRAZINONES, IMIDAZOUINOXALINES AND HETEROCYCLIC-SUBSTITUTED IMIDAZOPYRAZINES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-16 WO disclosed
US-20040180898-A1 Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines BRISTOL-MYERS SQUIBB COMPANY 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180898-A1 Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines NISCH, PDXK, IPO4 PLAUR 4844/4885KDM4E 1771/4885NPC1 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.